A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Latest Information Update: 19 Oct 2022
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Bladder cancer; Bone metastases; Carcinoma; Renal cancer; Squamous cell cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 22 Sep 2022 Status changed from active, no longer recruiting to completed.
- 14 Sep 2020 Planned End Date changed from 10 Aug 2020 to 1 Sep 2023.
- 06 Jul 2020 Primary endpoint (overall response rate) has been met.